BioSpace News Archive

Accuray Incorporated will report financial results for the fourth quarter and fiscal year 2021, ended June 30, 2021, after the market close on Wednesday, August 11, 2021.

Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal second quarter 2021 financial results after market close on Thursday, August 5, 2021.

Travere Therapeutics, Inc. announced that on July 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 89,950 shares of its common stock to eleven new employees, consisting of inducement stock options to purchase an aggregate of 65,100 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 24,850 shares of its common stock.

Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that Nathalie Adda, M.D., Senior Vice President and Chief Medical Officer, will retire from Enanta in February 2022 and continue to serve as a consultant to the company thereafter.

Incyte (Nasdaq:INCY) today announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM) demonstrating that treatment with ruxolitinib (Jakafi®) resulted in significantly improved outcomes in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (GVHD) compared to best available therapy (BAT).

Acutus Medical, Inc. announced the pricing of its underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $14.00 per share.

The global liver treatment market is expected to reach US$ 4,883.5 Mn in 2025 from US$ 3,426.8 Mn in 2017. The market is estimated to grow with a CAGR of 4.6% from 2018-2025.

The Medical Device Testing Services market was valued at US$ 5505.4 million in 2018 and it is projected to reach US$ 14,660.1 million by 2027; it is expected to grow at a CAGR of 11.7% from 2019 to 2027.

The global patient simulators market is expected to reach US$ 2,373.1 Mn in 2025 from US$ 694.6 in 2017. The market is estimated to grow with a CAGR of 16.8% from 2018-2025.

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the pricing of its initial public offering of 7,920,000 shares of its Class A common stock at a price to the public of $20.00 per share